Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Tumor Stage
研究概览
简要总结
An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Ecologic Or Community
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients older than 18 years with diagnosis of differentiated, medullary or anaplastic thyroid cancer confirmed by histopathology.
- •Patients who agree to participate and are able to understand the information sheet and sign the informed consent
排除标准
- •Patients under 18 years of age.
- •Patients with other types of thyroid cancer or whose histopathological diagnosis has not been confirmed.
- •Patients who do not have the relevant basic information to be included in the study, according to the criteria of the principal investigator.
结局指标
主要结局
Tumor Stage
时间窗: Baseline
From I to IV, based on the interpretation of the TNM classification and depending on the hystopathological characteristics of the tumor.
Situation of the tumor at first-diagnosis
时间窗: Baseline
Local tumor, locoregional tumor or metastatic disease.
Tumor-Node-Metastasis classification
时间窗: Baseline
Based on the AJCC (American Joint Committee on Cancer) 2018 TNM system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Hystopathological characteristics of the tumor
时间窗: Baseline
Based on pathologist evaluation of biopsy including differentiated, medullar or anaplasic.
次要结局
- Number of patients with PI3K mutation(12 months)
- Number of patients with PAX8/PAR mutation(12 months)
- Patient situation at the end of treatment(12 months)
- Number of patients with RAS mutation(12 months)
- Number of patients with P53 mutation(12 months)
- Number of patients with BRAF mutation(12 months)
- Number of patients with RET mutation(12 months)
- Number of patients with PTEN mutation(12 months)